Indomethacin for the Prevention of Symptomatic Patent Ductus Arteriosus in Very Low Birth Weight Infants

INDOMETHACIN對於極低體重早産兒症狀性存開性動脈導管之預防

賴聰宏(Tsung-Horng Lai) ； 宋文舉(Wen-Jue Soong) ； 黃碧桃(Betau Hwang)

《Acta Paediatrica Sinica》 31卷1期 (1990/02) Pp. 17-23

摘要

爲了解以口服Indomethacin預防極低體重早産兒發生症狀性存開性動脈導管的效果，研究32例出生體重750至1500公克，有呼吸窘迫症的早産兒，以隨機取樣的方法，實驗組15位早産兒在出生第24,36和60小時分別給予口服每公斤0.2克毫克的Indomethacin於1西西台灣啤酒溶液，對照組的17位早産兒在相同的時間給予口服1西西0.33%的氯化鈉葡萄醣溶液。
兩組的出生體重，妊娠週數，性別和呼吸窘迫嚴重的程度並無差別，但是實驗組14位存活的早産兒有兩例仍發生症狀性存開性動脈導管，而對照組的16位存活早産兒卻有9例發生症狀性存開性動脈導管。（P值小於0.05）
兩組發生肺增生不良，使用氧氣治療時間的長短，使用氣管插管的時間，體重回升的時間和發生合併症的情形並無差別。此結果顯示出以Indomethacin預防極低體重早産兒發生存開性動脈導管是有效的。

並列摘要

To assess the efficacy of prophylactic indomethacin in reducing the incidence of symptomatic patent ductus arteriosus, thirty two preterm infants weighing 750-1500gm at birth were randomized to receive oral indomethacin or placebo. Fifteen infants received oral indomethacin with a dosage of 0.2mg/kg at the 24th, 36th and 60th hour of age as the study group. The other 17 infants received I ml 0.33% saline in 5% G/W soultion at the same schedule. Birth weingt, gestational age, male/female ratio and severity of respiratory distress syndrome were similar for both groups. Nine of the 16 survivors of control group developed symptomatic patent ductus arteriosus. On the contrary, only two of the 14 survivors who received prophylactic indomethacin developed symptomatic PDA (P＜0.05).
There were no significant difference in the development of bronchopulmonary dysplasia, duration of oxygen therapy, duration of endotracheal intubation, days required to regain birth weight or complication between these two groups. The results indicated that the use of prophylactic oral indomethacin is beneficial in the prevention of symptomatic PDA in very low birth weight infant.

並列關鍵字

indomethacin ； patent ductus arteriosus ； very low birth weight infant